CAELYX 20 MG / 10 ML ( DOXORUBICIN 2 MG / ML ) CONCENTRATE FOR SOLUTION FOR IV INFUSION 10 ML VIAL

Welcome visitor you can login or create an account.

Example

Returns

You can return the product within 14 days of purchase.

Returns

You can return the product within 14 days of purchase.

Description Reviews (0)

CAELYX 20 MG / 10 ML ( DOXORUBICIN 2 MG / ML ) CONCENTRATE FOR SOLUTION FOR IV INFUSION 10 ML VIAL

Doxorubicin is a potent anthracycline chemotherapy medication derived from the bacterium Streptomyces peucetius. It is widely used to treat various cancers but requires rigorous monitoring due to its potential for serious side effects, particularly heart damage.

Medical Description and Mechanism

Classification: It is an antitumor antibiotic in the anthracycline class.
Mechanism of Action: It primarily works by DNA intercalation, where the molecule wedges itself between DNA base pairs. This inhibits the enzyme topoisomerase II, preventing cancer cells from repairing their DNA and effectively stopping cell replication. It also promotes the production of reactive oxygen species (ROS) (free radicals), which further damages cancer cell structures.
Pharmacokinetics: Doxorubicin is administered intravenously (IV) and follows a triphasic clearance pattern. It is primarily metabolized by the liver and excreted mainly through bile (40-50%) and, to a lesser extent, urine (5-12%).
Formulations: Common forms include standard doxorubicin hydrochloride and pegylated liposomal versions (e.g., Doxil), which are designed to reduce certain toxicities and stay in the bloodstream longer.

Therapeutic Indications
Doxorubicin is approved to treat a broad range of malignancies, including:

Solid Tumors: Breast, bladder, ovarian, gastric (stomach), thyroid, and lung cancers.
Hematological Cancers: Hodgkin and non-Hodgkin lymphomas, and various leukemias (ALL, AML).
Sarcomas: Soft tissue and bone sarcomas (such as Ewing's sarcoma and osteosarcoma).
Pediatric Cancers: Wilms' tumor and neuroblastoma.

Clinical Warnings & Safety

Cardiotoxicity: Doxorubicin has a Black Box Warning for dose-related heart damage. The risk of cardiomyopathy increases with the cumulative dose, and patients must undergo regular heart function tests (like ECHOs or MUGA scans).
Myelosuppression: It can severely decrease blood cell counts (white cells, red cells, and platelets), leading to a high risk of infection, anemia, and bleeding.
Extravasation: If the drug leaks out of the vein into surrounding tissue during infusion, it can cause severe tissue necrosis (tissue death) and permanent damage.
Urine Discoloration: Patients should expect their urine to turn a reddish-orange color for 1 to 2 days after treatment; this is harmless and due to the color of the drug itself.
Secondary Cancers: There is a small risk of developing secondary leukemias (AML or MDS) years after treatment.

Patient Medical Disclaimer:
The information provided here is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Doxorubicin is a high-risk medication that must only be administered by trained healthcare professionals in a clinical setting. Always consult with your oncologist or a qualified healthcare provider regarding your specific medical condition or treatment plan. Do not ignore professional medical advice or delay seeking it because of something you have read here. If you experience symptoms of an allergic reaction (such as difficulty breathing or swelling) or signs of heart trouble (shortness of breath or rapid heartbeat), seek emergency medical care immediately.